Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Henlius BiotechHKSE:02696 -1.10%67 Altman Z-Score is 2.76 as of Aug. 16, 2026, which is 151% above its 10-year median of 1.10. GuruFocus rates HKSE:02696 with a GF Score™ of 67/100 and a GF Value™ of HK$30.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 927 Biotechnology companies, Shanghai Henlius Biotech ranks better than 50.92% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 2.76 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
Shanghai Henlius Biotech has a Altman Z-Score of 2.76, indicating it is in Grey Zones. This implies that Shanghai Henlius Biotech is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Shanghai Henlius Biotech's Altman Z-Score or its related term are showing as below:
HKSE:02696'
s Altman Z-Score Range Over the Past 10 Years
Min: -0.42 Med: 1.1 Max: 6.19
Current: 2.76
During the past 9 years, Shanghai Henlius Biotech's highest Altman Z-Score was 6.19. The lowest was -0.42. And the median was 1.10.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02696 vs VRTX, REGN, RVMD: Altman Z-Score Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Shanghai Henlius Biotech (HKSE:02696) has a Altman Z-Score of 2.76 as of Aug. 16, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shanghai Henlius Biotech and its competitors. This is 151% above median its historical median of 1.10. According to the industry distribution chart, Shanghai Henlius Biotech ranks #455 out of 927 companies in the Biotechnology industry, placing it in the top 49.1%.
Is Shanghai Henlius Biotech's Altman Z-Score too high?
Shanghai Henlius Biotech's current Altman Z-Score of 2.76 is 151% above median its 10-year median of 1.10. The Biotechnology industry median Altman Z-Score is 2.62. Shanghai Henlius Biotech's value of 2.76 is 5.3% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #455 out of 927 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #455 out of 927 companies for Altman Z-Score. This puts Shanghai Henlius Biotech in the upper half of its industry. The industry median Altman Z-Score is 2.62. Shanghai Henlius Biotech's value of 2.76 is 5.3% above this benchmark. While the company's 10-year median is 1.10 vs. the industry median of 2.62, Shanghai Henlius Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.62, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current Altman Z-Score of 2.76 is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current Altman Z-Score is 2.76, which is 151% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current Altman Z-Score is 2.76, which is 151% above median its 10-year median of 1.10 and 5.3% above the Biotechnology industry median of 2.62. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current Altman Z-Score is 2.76 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:02696:
Altman Z-Score: 2.76 (151% above median its 10-year median of 1.10)
GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
Industry Position: 5.3% above the Biotechnology median (#455 of 927)
No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score
Get the complete analysis for HKSE:02696
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02696 has been successfully added to your 
